Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating restated by UBS AG in a research report issued on Thursday, www.flashratings.com reports. They presently have a $46.00 price target on the stock, down from their previous price target of $50.00. UBS AG’s price target would indicate a potential upside of 42.46% from the company’s previous close.
Other equities analysts also recently issued reports about the company. Deutsche Bank AG dropped their price objective on Mylan N.V. from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, April 18th. Morgan Stanley dropped their price objective on Mylan N.V. from $52.00 to $36.00 and set an “equal weight” rating for the company in a research note on Monday. Royal Bank Of Canada set a $41.00 price objective on Mylan N.V. and gave the company a “hold” rating in a research note on Saturday, May 13th. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Thursday, May 25th. Finally, ValuEngine downgraded Mylan N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $47.83.
Shares of Mylan N.V. (NASDAQ MYL) traded up 0.65% during mid-day trading on Thursday, hitting $32.29. The company had a trading volume of 12,306,610 shares. The firm has a 50-day moving average price of $37.74 and a 200 day moving average price of $39.09. Mylan N.V. has a 12 month low of $29.58 and a 12 month high of $49.42. The firm has a market capitalization of $17.31 billion, a P/E ratio of 32.26 and a beta of 1.27. Mylan N.V. also was the recipient of some unusual options trading on Monday. Stock traders acquired 9,410 call options on the stock. This is an increase of 250% compared to the average daily volume of 2,688 call options.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.18 by $0.08. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same period in the previous year, the business earned $1.16 earnings per share. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, equities research analysts forecast that Mylan N.V. will post $4.86 earnings per share for the current fiscal year.
In other Mylan N.V. news, President Rajiv Malik sold 25,000 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the transaction, the president now owns 799,855 shares in the company, valued at $31,994,200. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the sale, the insider now directly owns 140,653 shares in the company, valued at $5,626,120. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.
Several hedge funds have recently made changes to their positions in MYL. First Personal Financial Services raised its stake in shares of Mylan N.V. by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock worth $107,000 after buying an additional 681 shares during the last quarter. Global X Management Co. LLC raised its stake in shares of Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock worth $118,000 after buying an additional 1,441 shares during the last quarter. Ropes Wealth Advisors LLC acquired a new stake in shares of Mylan N.V. during the first quarter worth about $136,000. Oakworth Capital Inc. raised its stake in shares of Mylan N.V. by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock worth $166,000 after buying an additional 1,000 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Mylan N.V. during the first quarter worth about $188,000. 70.19% of the stock is currently owned by institutional investors and hedge funds.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.